ABSTRACT Objectives: To determine the body mass, cardiovascular and metabolic characteristics of young people presenting for mental healthcare.
INTRODUCTION
There is international recognition of the premature death and disability attributable to mental disorders-reflecting their early ageof-onset, high population prevalence, chronicity and comorbidity with physical illness. 1 2 Much of the increased risk to premature death that is not accounted for by suicide or other accident or injury is due to premature cardiovascular disease. 3 4 To reduce total illness burden due to mental disorders, active primary and secondary risk reduction, earlier identification of disorder and enhanced longterm care are now recognised international priorities. 1 5-9 While the reduction in premature death or ongoing disability directly attributable to mental ill-health has been emphasised, [10] [11] [12] far less focus has been directed towards development of early interventions to reduce poor physical health outcomes. This is despite strong evidence of increased rates of all-cause mortality, and, most notably, increased rates of premature cardiovascular morbidity. 13 14 The pathways to increased cardiovascular
Strengths and limitations of this study
▪ A cross-sectional study of a large number of young persons with emerging mental disorders seeking primary-care based health services. ▪ The findings in this younger age group, early in the course of care, are substantially different from those with established mental disorders. ▪ While evidence for a possible relationship between exposure to medication and being overweight or obese was detected, a larger sample and a longitudinal design are required to elaborate the nature of this cross-sectional relationship. ▪ The study results suggest that a populationhealth focused strategy is required to prevent the onset of metabolic or cardiovascular disorders.
disease are complex. Among those with established mental disorders these include: increased exposure to known risk factors (eg, smoking, obesity, low physical activity); less active management of other risk factors (eg, glucose intolerance, dyslipidaemia, hypertension); and, the adverse impacts of other intrinsic factors (eg, disturbed circadian rhythm; perturbed sympathetic and parasympathetic nervous system regulation or increased chronic inflammation). [15] [16] [17] [18] Of additional concern is the potential adverse effects of early or continued exposure to medical treatments (eg, second generation antipsychotics, some antidepressants) that may impart increased risk of obesity, glucose intolerance or a broader metabolic syndrome.
Internationally, there has been increasing focus on the increasing rates of being overweight or obese among young people, particularly those living in developed countries. The pathways linking these changes in body mass in childhood and premature cardiovascular disease in adulthood are themselves complex. They are likely to include direct effects of childhood or teenage obesity on the early development of glucose intolerance, hypertension, dyslipidaemia or chronic inflammation as well as the indirect effects of predisposing the young person to obesity as an adult. 19 Importantly, such pathways are not inevitable and lend themselves to the development of active intervention strategies, particularly during the adolescent or early adult period.
By contrast with evidence from middle-aged persons with established psychotic or mood disorders of increased rates of smoking, obesity, hypertension, other vascular risks or impaired metabolic parameters, 16-18 20 there is little data describing these same parameters in large numbers of young people presenting for mental healthcare with common anxiety or mood disorders. Further, there is relatively little information available exploring the potential links between the nature of the mental disorder (eg, depressive subtypes, psychotic disorder) or the stage of illness 21 7 and the pattern of risk factors evident. Therefore, in the context of developing new and enhanced primary-care based mental health services for young people in the early phases of major disorders 22 23 we are examining the rates of altered body mass, cardiovascular function and glucose and lipid profiles and studying cross-sectional and longitudinal patterns of association with illness type, duration and exposure to other treatments.
METHODS
Participants (aged 12-30 years) were recruited from either the headspace Campbelltown (outer suburban, South Western Sydney) or Camperdown (inner urban; co-located with the Brain & Mind Research Institute) site. These young people were referred by general practitioners (GPs), paediatricians, schools, welfare agencies, family/friends or they were self-referred. All participants gave prospective written informed consent for their clinical data to be used for research purposes. Parental consent was obtained for participants under 18 years of age.
Measures
Part clinical information was obtained via: (1) a brief selfreport questionnaire and/or (2) a clinical assessment. Detailed methods have been set out previously. 8 24-26 On presentation to the headspace site, participants were weighed and measured (in height) to ascertain their body mass index (BMI). In addition, blood pressure (BP) was taken by a health professional as part of their routine assessment and pathology requests were made by the referring clinician (ie, IH, ES or headspace GP) to obtain the following standard laboratory lipid values: low-density lipoprotein (LDL), high-density lipoprotein (HDL), cholesterol (CHOL) and triglyceride (TG). Fasting glucose >5.5 mmol/L was considered 'impaired' as recommended by an American Diabetes Association (ADA) expert committee. 27 28 Allocation to clinical subtypes An independent reviewer (DFH) allocated cases to one of the three proposed subgroups 23 on the basis of the description of the clinical presentation alone. Any cases presenting with depressive symptoms only, with no evidence of psychotic or manic features and no indication of atypical symptoms were allocated to the anxiousdepression (ANX-DEP) group. The developmentalpsychotic (DEV-PSY) group is hypothesised to be associated with autism, schizophrenia and/or psychotic phenomena. [29] [30] [31] [32] Any cases with manic-like symptoms (manic, hypomanic or brief hypomanic phenomena) are preferentially allocated to the mania-fatigue (MAN-FAT) subtype irrespective of past or current evidence of psychotic or other phenomena. We employ the fatigue (FAT) label as the individual characteristics that most frequently differentiate the trajectories as the atypical features of depression, especially reduced activation and energy, and increased need for sleep, etc. [33] [34] [35] The revised Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria recognise the importance of activation as a cardinal feature of bipolarity, which is often a manifestation of underlying circadian rhythm dysregulation. 36 37 The final (and here residual) subtype comprises individuals who frequently reported childhood anxiety, but later show evidence of heightened stress-sensitivity and an evolving depressive disorder (but without evidence of a 'fatigue' profile); this is the ANX-DEP subtype. 22 
Data reduction
As a means to compare data to the general population, participants were collapsed into the following age groups-depending on the measure of interest. 
Statistical analyses
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS V.21, IBM Corp). Group differences in demographic, clinical and metabolic variables were assessed via t test, analysis of variance (ANOVA) or χ 2 tests where relevant. If homogeneity of variance was violated (eg, according to Levene's test) the corrected degrees of freedom and p values were calculated using Welch's correction. To analyse the relationships between metabolic variables (BMI, fasting glucose, total cholesterol, BP, pulse rate) and demographics (sex, age), socio-occupational functioning (Social and Occupational Functioning Assessment Scale, SOFAS), psychological distress (K-10), and smoking status we performed multiple linear regression (MLR) analyses utilising the 'enter' method. All analyses were two tailed and employed an α level of 0.05.
RESULTS
Inclusion in this sample has been determined by presence of a recording of BMI in participants between the ages of 12 and 30 years (median age=19.0 years; mean age=19.0 years; SD=3.5 years). As the number of other cardiovascular or metabolic risk factors recorded in these participants varied, the results are presented in order of completeness of data.
Body mass index BMI recordings were available for 1005 individuals, including 62% females (n=625, mean age=18.9±3.5 years) and 38% males (n=380, mean age=19.2±3.6 years). There was no significant difference in BMI between females (23.6 ±5.7) and males (24.0±5.5); (t(1003)=−1.2, p=0.755). Both females and males showed a small but significant correlation between older age and higher BMI (r=0.147, n=625, p<0.001; r=0.113, n=380, p<0.05; respectively). With regards to the distribution of cases across BMI categories within each gender, there was a higher proportion of males (37.1%; 141/380 vs females: 30.2%; 189/625) in the overweight/obese category and a higher proportion of females in the normal (females: 59.8% vs males: 55.8%) and underweight (females: 9.9% vs males: 7.1%) categories. The overall χ 2 test for this crosstab (cases within each gender by BMI category) was significant (χ 2 (1005)=6.2, p=0.046).
We tested for differences in other demographic, clinical and cardiovascular risk characteristics across these BMI categories (table 1) . Notably, current social and occupational function (SOFAS) was most impaired in those who were overweight or obese. For the set of demographic and clinical predictors of BMI examined, linear regression analyses demonstrated only two significant predictors-namely age (β=0.144, p<0.01) and SOFAS (β=−0.134, p<0.05) with the overall model (F(5,379)=3.6, p<0.005) explaining only 4.6% of the variance (adjusted R 2 =0.033). Figure 1 shows the proportions of cases within the BMI categories in our youth mental health sample ('YMH') as compared to their age-matched peers in the Australian general population. 38 Among these comparisons, there are two notable differences: (1) YMH had a smaller proportion of 12-15-year-olds in the 'underweight/normal' group compared to the general population (62.6% vs 73.2%; figure 1); and (2) YMH sample had a smaller proportion of overweight 18-24-year-olds compared to the general population (18.7% vs 25.1%; figure 1 ).
Current medication status was available for a subset (N=129) of individuals, of whom, 65.9% (N=85) were underweight or normal weight and 34.1% (N=44) were overweight or obese. These two groups (ie, underweight/normal weight vs overweight/obese) were significantly ( p<0.001) different in age (19.1±3.8 years vs 21.2±4.1 years, respectively) but they did not differ in the proportion of each gender (70.6% vs 59.1% females, respectively). Thus, 2×2×2 χ 2 analyses were conducted to determine whether the major BMI groups differed in medication status while controlling for age (as a categorical variable: 12-19 vs 20-30 years). For nil versus 'any psychotropic medication' the overall (ie, 2×2) model was significant (χ 2 (1,129) =5.3, p=.024), whereby 84.1% of those in the overweight/obese category were currently medicated, 
Fasting glucose, CHOL, TG, HDLs and LDLs
One-third (29.6%; 298/1005; N=190 females) of cases with BMI data also had their fasting bloods collected. As shown in table 2, there were significant differences among the BMI categories for TGs and HDL, but no differences in the glucose or LDL levels. Compared to the other two groups, the overweight/obese group had the highest levels of the TGs and the lowest levels of HDL. There were significant differences between females and males in terms of their fasting glucose (males higher; t=−2.50, df=296, p<0.05) and HDL (males lower; t=6.58, df=209.1, p<0.001) but not in their total cholesterol, TGs and low-density lipoproteins. There was a significantly (χ 2 =7.9, df=298, p=.005) higher proportion of males (9.3%) compared to females (2.1%) with a fasting glucose level ≥5.5 mmol/L. There was no significant difference in the proportion of females versus males with high levels (≥2.0) of TGs (6.5% and 7.7%, respectively). In terms of the lipoprotein thresholds, while the proportion of females (4.0%) and males (3.6%) with high (>4.0) levels of LDL did not differ, there was a significantly (χ 2 =32.2, df=237, p<0.001) higher proportion of males (34.1%) compared to females (5.9%) with low levels (≤1.0) of HDL.
The relationship between BMI and fasting glucose levels was non-significant for both females (r=0.102, n=190, p=0.16) and males (r=0.119, n=108, p=0.22). Of note, these associations (in each gender) remained nonsignificant when the cases with underweight BMI scores were excluded from the bivariate analyses. By contrast, for females there were significant correlations between BMI and all three CHOL variables: TG (r=0.165, n=184, p<0.05), LDL (r=0.169, n=150, p<0.05) and HDL (r=−0.268, n=152, p<0.001) levels. In males, only TG levels were correlated with BMI (r=0.328, n=104, p<0.01). Furthermore, all of these correlations remained significant when the underweight cases were removed from the analyses.
The MLR model for fasting glucose was found to be non-significant. For total cholesterol, the overall model (F (6, 
Developmental phenotypes and clinical stage
More than three-quarters of the sample (N=775 cases) were classified according to our tripartite model of developmental psychopathology. Of these, just under 70% (n=541) met criteria for the ANX-DEP subtype, 13.4% (n=104) met criteria for 'mania-fatigue/atypical depression' and 16.8% (n=130) were in the 'developmentalpsychotic' category. Table 3 outlines the demographic, clinical and physical health aspects of these three subgroups. There was a significant difference in the gender ratio among the tripartite groups (p<0.001; see , with the MAN-FAT group having the highest proportion (70.2%) and the DEV-PSY the lowest proportion of females (40.0%). While the MAN-FAT group was the oldest (20.8±3.5 years) and DEV-PSY the youngest (at 18.8 ±4.0 years), the latter also showed the lowest levels of socio-occupational function with the lowest levels of psychological distress (K-10) compared to the other two subgroups. Notably, there were no differences among the diagnostic subgroups groups in terms of mean BMI and BP/PR (including after controlling for the potential effects of age and gender). This overall pattern remained in the subset of patients who also had their bloods taken (N=261). Of note, there were no significant differences among the subgroups in terms of their mean clinical bloods measures (ie, glucose, TGs, LDL and HDL; see table 4 ).
DISCUSSION
This report outlines the distribution of BMI (n=1005), cardiovascular risk (n=739) and other metabolic characteristics (n=298; within a month of the BMI measurement) in young people presenting early in the course of common anxiety, mood or psychotic disorders. These data are critical to advancing our understanding of the developmental pathways to increased rates of premature ischaemic heart disease and the planning of cohort-based and individual clinical programmes to change those paths. While a third (330/1005) of the young people are overweight or obese, this is not substantially different to the aged-matched general population in Australia and, surprisingly, there is no clear association (at least at this early stage of mental illhealth) between increasing BMI and raised fasting glucose. However, we did find a pattern of high TGs and low HDL levels in those who were overweight/obese, which is typically observed in this group. 19 Furthermore, smoking emerges as a major risk factor with 30% of all participants smoking daily compared with ∼11% reported for this age-based cohort in Australia. 39 While the general pattern of associations in this sample do show slowly increasing other cardiovascular and metabolic risks among males, as well as with increasing age and increasing social and occupational disability, the overall pattern strongly suggests the need for preventive interventions (other than smoking cessation) to be directed at the whole group rather than selected on the basis of individual risk profiling. This is consistent with the emerging fields of how best to modify those risks in other young people who are currently overweight or obese or have metabolic profiles that may be indicative of somewhat increased longer-term risk of poor cardiovascular health. 19 28 40 A common assumption in current mental health practice is that those at greatest risk of developing cardiovascular disease or metabolic disturbance do so as a consequence of weight gain that results from illnessdependent factors such as decreased activity levels, increased food intake or other medication dependent effects. The findings of a lack of correlation between BMI and fasting glucose in males and females are therefore worthy of further consideration. In younger participants, it may be consistent with the notion that at this stage of life, and of illness duration, raised glucose levels are due largely to unrelated genetic influences, as well as the fact that many of those with higher BMIs are not yet insulin resistant. This is a situation, however, that may change quickly if the mental disorder persists or medications with adverse metabolic effects (eg, second generation antipsychotics, some antidepressants) are prescribed to treat the primary mental disorder or the person develops other comorbid behaviours such as increased food intake, lowered levels of physical activity or perturbed circadian rhythms. From a developmental and diagnostic perspective, it is important to consider whether some individuals are at greater risk of gaining weight or developing other indicators of metabolic or cardiovascular risk as a direct consequence of their illness-type. For example, those with marked circadian disruption (as seen in atypical depression or bipolar disorder, here captured in the 'mania-fatigue' subtype, or as part of a psychotic disorder, here captured as 'developmental-psychotic') might be expected to be at particular risk of increased BMI and associated metabolic disturbance very early in their illness course. Within the limitations of this crosssectional study, however, we were not able to detect major differences in BMI or metabolic or cardiovascular risk on the basis of diagnostic-developmental subtype. However, those younger participants did appear to have somewhat lower risk, consistent with the notion that risk accumulates in association with illness progression, chronicity or concurrent treatments. Other limitations of the present study include: (1) a lack of a comparison group (eg, healthy individuals seeking care); (2) potential selection biases (eg, differences in those who decided to undergo blood tests vs those that did not); (3) generalisability (eg, these results may not be relevant to young people with mental health problems in other settings and/or countries). Future studies should aim to address these issues.
The findings reported here of relatively normal patterns of BMI and other metabolic and cardiovascular risk factors in this population are very different from those that are commonly reported in middle-aged persons receiving specialist care for psychotic or major mood disorders. This suggests that younger age and/or earlier stages of illness are likely to be key factors underlying such patterns. However, there is evidence of metabolic abnormalities and increased cardiovascular risk in young people with first episode psychotic attending early intervention or other specialised mental health services. 3 4 41 Of note, a US study of 76 young, first episode psychosis (schizophrenia) patients attending an urban community mental health centre were found, at entry, to have comparable metabolic profiles to their community peers. 42 However, over the course of the subsequent year, these patients had a significant worsening of cardiovascular risk factors (especially, smoking and obesity). In much of the early psychosis literature, the first year following onset has been described as the 'critical period' [42] [43] [44] for the delivery of optimal interventions to prevent excess morbidity and early mortality. This concept has not been extended to include improved physical as well as mental health and other functional outcomes.
More recently, there have been major refinements to the concepts of prodromal and critical periods for early psychosis to include the more elaborated notion of clinical staging, thereby capturing a greater continuum of the journey from early symptoms to established illness 11 Further, the concept has been broadened to include young people with emerging mood disorders. 10 45 Within this framework, the greatest opportunities for modifying the course of illness, including physical health comorbidity, are extended to include a wider spectrum of earlier periods of disabling symptoms and the more obvious early periods of discrete disorder. A priority for early intervention research now is to evaluate whether group or individual-level interventions at these very early stages may help to reduce smoking rates or prevent the increased rates of being overweight or obese or of other specific metabolic complications that are common in those young people presenting for specialist mental healthcare.
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